Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
Published version of a preprint
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“What is more, nucleotide-resolution mapping of breakpoints revealed microhomology-mediated repair in both genotypes, consistent with AID-dependent B-cell neoplasms and MM79,80, with Dis3G766R/+ cells (Supplementary Fig. S8c) exhibiting modestly longer microhomologies (7 bp vs. 5 bp in WT), suggestive of increased reliance on alternative end joining.”
From DIS3 mutations enhance AID-driven translocations during B-cell activation, promoting transformation to multiple myeloma (2026) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Reactome pathway Knowledgebase
Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1351 · Cited by 5,605
Gene Ontology Consortium: going forward
The Gene Ontology Consortium (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1179 · Cited by 3,492
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Xie, X., Lu, J., Kulbokas, E. J., Golub, T. R., Mootha, V., Lindblad-Toh, K., Lander, E. S., & Kellis, M. (2005) · Nature · doi:10.1038/nature03441 · Cited by 1,872
Lee, J. A., Carvalho, C. M. B., & Lupski, J. R. (2007) · Cell · doi:10.1016/j.cell.2007.11.037 · Cited by 914 · cited 1×
“Short homologous sequences are indicative of MMEJ,(42) rather than NHEJ, and result from fork stalling and template switching during DNA replication or through microhomology-mediated break induced repair.(43,44) The proteins involved in MMEJ include PARP1, Rad50, and Ercc1, whereas MMEJ is inhibited by functional ATM,…”
BackgroundThe genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913 · cited 1×
“tiating events and involve rearrangements of the immunoglobulin heavy chain (IGH) locus on 14q32.(1) The partners of these rearrangements include 11q (CCND1,”
BackgroundSelf-citationHastings, P. J., Ira, G., & Lupski, J. R. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000327 · Cited by 818 · cited 1×
“Short homologous sequences are indicative of MMEJ,(42) rather than NHEJ, and result from fork stalling and template switching during DNA replication or through microhomology-mediated break induced repair.(43,44) The proteins involved in MMEJ include PARP1, Rad50, and Ercc1, whereas MMEJ is inhibited by functional ATM,…”
BackgroundMultiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
IRF4 addiction in multiple myeloma
Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008) · Nature · doi:10.1038/nature07064 · Cited by 730
Walker, B. A., Boyle, E. M., Wardell, C. P., Murison, A., Begum, D. B., Dahir, N. M., Proszek, P. Z., Johnson, D. C., Kaiser, M. F., Melchor, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1503 · Cited by 567 · cited 2×
“38738_RNAS_51065_1-AS-RB-CD138-DNA_CD138_KP-088MT t(2;8) chr2: CTGCTAGAGAGAGTTATGATCTCGCCACTGCACTCCACCCTGTGTGACAGAGTGAGACTC |||||||||||||||||||| | | || || | || | | KP088: CTGCTAGAGAGAGTTATGATGAGTGGGACCAAGTGCAATAGGTCTATGTCCAGGATAATT | | ||||||||||||||||||||||||||||||||||||||||||| chr8: CATCCTTGACTCATCCAGATGAGTGGGACCAAG…”
Self-citation
Cited by
MYC as a target for cancer treatment
Duffy, M. J., O'Grady, S., Tang, M., & Crown, J. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102154 · Cited by 514
The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma
Isa, R., Horinaka, M., Tsukamoto, T., Mizuhara, K., Fujibayashi, Y., Taminishi-Katsuragawa, Y., Okamoto, H., Yasuda, S., Kawaji-Kanayama, Y., Matsumura-Kimoto, Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062919 · Cited by 11
Kuliński, T. M., Gewartowska, O., Mahé, M., Kasztelan, K., Durys, N., Stroynowska-Czerwińska, A., Jedynak-Slyvka, M., Owczarek, E. P., Chaudhury, D., Nowotny, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70386-3 · Cited by 7
Metadata
- Authors
- Mikulasova, A., Ashby, C., Tytarenko, R. G., Qu, P., Rosenthal, A., Dent, J. A., Ryan, K. R., Bauer, M. A., Wardell, C. P., Hoering, A., Mavrommatis, K., Trotter, M., Deshpande, S., Yaccoby, S., Tian, E., Keats, J., Auclair, D., Jackson, G. H., Davies, F. E., Thakurta, A., Morgan, G. J., & Walker, B. A.
- Venue
- Haematologica
- Published
- 2019-06-20
- Volume
- 105
- Issue
- 4
- Pages
- 1055-1066
- ISSN
- 0390-6078
- 1592-8721
- Cited by
- 63
- References
- 13
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma. https://app.cochat.ai/papers/10.3324/haematol.2019.217927
- The paper
- Mikulasova, A., Ashby, C., Tytarenko, R. G., Qu, P., Rosenthal, A., Dent, J. A., Ryan, K. R., Bauer, M. A., Wardell, C. P., Hoering, A., Mavrommatis, K., Trotter, M., Deshpande, S., Yaccoby, S., Tian, E., Keats, J., Auclair, D., Jackson, G. H., Davies, F. E., . . . Walker, B. A. (2020). Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma. Haematologica. https://doi.org/10.3324/haematol.2019.217927
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.